CLSA cuts Dr. Reddy's stock rating to Underperform
CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...
CLSA lowers Dr. Reddy's shares price target, citing lack of near-term growth triggers
CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...
CLSA selects Apollo Hospitals as top pick, says India's pharma set to outpace US growth
The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...
The Financial Express14h
HUL drops to 8-month low on margin concerns
Taking a more bearish stance, CLSA has downgraded HUL to an Underperform rating. The brokerage firm also has slashed its ...
The Edge Singapore14h
Re-union of the Snake
There is mild anticipation that as the Snake year slithers in, the local IPO markets will open up, and the STI will hit a new ...
Street positive on HDFC Bank results, CLSA has a 'Hold', HSBC lowers target but keeps 'Buy' call
This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...
ndtvprofit16h
Stock Recommendations Today: HUL, HDFC Bank, BPCL, Persistent Systems On Brokerages' Radar
NDTV Profit tracks what analysts are saying about various stocks and sectors. Here are the analyst calls to keep an eye out ...
cnbctv1816h
Only one analyst expects HUL shares to fall below ₹2,000; check price targets here
Out of the 43 analysts that now have coverage on HUL, 27 of them have maintained a 'Buy' rating on the stock, while 13 of ...